openPR Logo
Press release

Treatment-Resistant Depression Market Dynamics and Future Outlook | Key Players: Pfizer Inc., Viatris Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company

01-16-2025 02:27 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Treatment-Resistant Depression Market

Treatment-Resistant Depression Market

Treatment-Resistant Depression Market is anticipated to witness a significant growth during the forecast period.

Treatment-Resistant Depression Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future.

Get a Free Sample PDF copy of the report - https://datamintelligence.com/download-sample/treatment-resistant-depression-market

The Treatment-Resistant Depression market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.

Treatment-resistant depression (TRD) is a form of depression that does not improve with standard treatments, such as antidepressant medications or psychotherapy. Individuals with TRD continue to experience persistent depressive symptoms despite trying multiple treatments over a prolonged period.

Forecast Growth Projected:

The Global Treatment-Resistant Depression Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

List of the Key Players in the Treatment-Resistant Depression Market: Pfizer Inc., Viatris Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Otsuka America Pharmaceutical, Inc., AstraZeneca, Camber Pharmaceuticals, Inc., Biodesix and Validus Pharmaceuticals LLC.

Segment Covered in the Treatment-Resistant Depression Market:

➠ By Drugs {Antipsychotics (Aripiprazole (Abilify), Brexpiprazole (Rexulti), Quetiapine (Seroquel), Olanzapine (Zyprexa), Selective Serotonin Reuptake Inhibitors (SSRIs) (Fluoxetine (Prozac), Sertraline (Zoloft), Citalopram (Celexa), Paroxetine (Paxil), Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) (Duloxetine (Cymbalta), Venlafaxine (Effexor XR), Desvenlafaxine (Pristiq), Monoamine Oxidase Inhibitors (MAOIs) (Phenelzine (Nardil), Isocarboxazid (Marplan), Others}

➠ By Route of Administration (Oral, Injectable, Others)

➠ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Market Dynamics:

Developed economies have been experiencing rapid advancements in their healthcare sectors, driven by increased investments, higher income levels, and improved infrastructure. The demand for treatments targeting conditions like treatment-resistant depression has grown significantly, partly due to the rising prevalence of lung cancer. Key factors contributing to market growth include collaborations, acquisitions, and product launches, often fueled by technological advancements across various countries.

On January 30, 2023, Rexulti (brexpiprazole) received a new indication for the treatment of depression and depressive states, as submitted by Otsuka Pharmaceutical Co., Ltd. in Japan. The treatment is intended for patients who have not responded well to prior antidepressant therapy. In a phase 3 clinical trial, the safety and efficacy of brexpiprazole as an adjunctive therapy were evaluated in 740 adult patients with major depressive disorder (MDD) from Japan, aged 20 to 64.

Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=treatment-resistant-depression-market

Regional Break out:

The global Treatment-Resistant Depression Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico
☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe
☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific
☞ South America- Brazil, Argentina, Colombia, Rest of South America
☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Treatment-Resistant Depression manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Treatment-Resistant Depression in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Speak to Our Senior Analyst and Get Customization in the report as per your requierments: https://datamintelligence.com/customize/treatment-resistant-depression-market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Treatment-Resistant Depression market?

➠ Who are the global key manufacturers of the Treatment-Resistant Depression Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Treatment-Resistant Depression market opportunities and threats faced by the vendors in the global Treatment-Resistant Depression Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Treatment-Resistant Depression market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Treatment-Resistant Depression Market Dynamics and Future Outlook | Key Players: Pfizer Inc., Viatris Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company here

News-ID: 3818551 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Electrophysiology Market Business Outlook and Growth Projections through 2031 | Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Siemens Healthineers AG
Electrophysiology Market Business Outlook and Growth Projections through 2031 | …
The global electrophysiology market reached US$ 8.24 billion in 2023 and is expected to reach US$ 23.0 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033. The Electrophysiology market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging
US Silicone Breast Implants Market on Track for Strong Growth at a CAGR of 7.7% During 2024-2031 | Key Players- Allergan Inc., Mentor Worldwide LLC, Sientra, Inc.
US Silicone Breast Implants Market on Track for Strong Growth at a CAGR of 7.7% …
The US Silicone Breast Implants Market reached US$ 551.0 million in 2023 and is expected to reach US$ 995.1 million by 2031, growing at a CAGR of 7.7% during the forecast period 2024-2031. The US Silicone breast implants market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination
Wound Care Market Projected Strong Growth with Notable CAGR Forecast for 2024-2031 | Smith & Nephew PLC., Molnlycke Health Care Ab, Baxter International Inc.
Wound Care Market Projected Strong Growth with Notable CAGR Forecast for 2024-20 …
Global Wound Care Market reached US$ 18.5 billion in 2023 and is expected to reach US$ 25.4 billion by 2031, growing with a CAGR of 4.5% during the forecast period 2024-2031. The Wound Care market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging
Tardive Dyskinesia Treatment Market Scope and Competitive Analysis Forecast through 2024-2031 | Pfizer Inc., Biogen, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca
Tardive Dyskinesia Treatment Market Scope and Competitive Analysis Forecast thro …
The Tardive Dyskinesia Treatment Market is expected to Reach a CAGR of 4% during the forecast period (2024-2031).  The tardive dyskinesia treatment market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination of qualitative and quantitative research methods, the company offers comprehensive

All 5 Releases


More Releases for Depression

Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned. Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%